文献速递神经肌肉病

极低残留抗肌萎缩蛋白量与较轻型抗肌萎缩蛋白病相关

Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy.
PubMed 文献 · Ann Neurol · 2020-11-24

本研究为法国多中心回顾性队列研究,纳入90例DMD基因突变且具备肌肉活检Western blot数据的患者,按抗肌萎缩蛋白水平分三组。结果显示抗肌萎缩蛋白量<5%(甚至<0.5%)与多数临床结局较轻相关,包括丧失行走年龄(p<0.001),提示极低残留蛋白量可使表型从DMD向BMD偏移。

要点

  • 抗肌萎缩蛋白量<5%与较轻表型相关,包括丧失行走年龄延迟(p<0.001)。
  • 无抗肌萎缩蛋白组74%发展为DMD,<5%组61%发展为BMD。
  • ≥5%组多数在24岁后仍可行走,仅4例丧失行走能力。

核心结论

  • 极低残留抗肌萎缩蛋白量可使疾病表型从DMD向BMD偏移。

研究设计与样本

  • 法国多中心回顾性队列研究,利用Universal Mutation Database-DMD France数据库,纳入90例DMD基因突变且有肌肉活检Western blot数据的患者。

主要发现

  • 42例无抗肌萎缩蛋白(A组),其中31/42(74%)发展为DMD。
  • 34例抗肌萎缩蛋白量<5%(B组),其中21/34(61%)发展为BMD。
  • 抗肌萎缩蛋白量<5%(低至<0.5%)与多数临床结局较轻相关,包括丧失行走年龄(p<0.001)。

临床怎么用

  • 对于DMD基因突变患者,肌肉活检Western blot显示极低残留抗肌萎缩蛋白量(<5%)可能提示较轻的表型,有助于预后咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to determine whether a low residual quantity of dystrophin protein is associated with delayed clinical milestones in patients with DMD mutations. METHODS: We performed a retrospective multicentric cohort study by using molecular and clinical data from patients with DMD mutations registered in the Universal Mutation Database-DMD France database. Patients with intronic, splice site, or nonsense DMD mutations, with available muscle biopsy Western blot data, were included irrespective of whether they presented with severe Duchenne muscular dystrophy (DMD) or milder Becker muscular dystrophy (BMD). Patients were separated into 3 groups based on dystrophin protein levels. Clinical outcomes were ages at appearance of first symptoms; loss of ambulation; fall in vital capacity and left ventricular ejection fraction; interventions such as spinal fusion, tracheostomy, and noninvasive ventilation; and death. RESULTS: Of 3,880 patients with DMD mutations, 90 with mutations of interest were included. Forty-two patients expressed no dystrophin (group A), and 31 of 42 (74%) developed DMD. Thirty-four patients had dystrophin quantities < 5% (group B), and 21 of 34 (61%) developed BMD. Fourteen patients had dystrophin quantities ≥ 5% (group C), and all but 4 who lost ambulation beyond 24 years of age were ambulant. Dystrophin quantities of <5%, as low as <0.5%, were associated with milder phenotype for most of the evaluated clinical outcomes, including age at loss of ambulation (p < 0.001). INTERPRETATION: Very low residual dystrophin protein quantity can cause a shift in disease phenotype from DMD toward BMD. ANN NEUROL 2021;89:280-292.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. de Feraudy Y, Ben Yaou R, Wahbi K, et al. Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy. Ann Neurol. 2020. PMID: 33159473. doi:10.1002/ana.25951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。